NIKKEI 225
38,851.02 +233.92 (+0.61%) HANG SENG
18,989.37 -206.23 (-1.07%) CRUDE OIL
76.86 -0.71 (-0.92%) GOLD FUTURES
2,373.40 -19.50 (-0.81%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,614.45 -466.91 (-0.85%)
Immunome, Inc. (IMNM)
After hours:
| Previous close | 13.65 |
| Open | 14.75 |
| Bid | 14.40 x 100 |
| Ask | 14.44 x 200 |
| Day's range | 14.39 - 15.45 |
| 52-week range | 4.50 - 30.96 |
| Volume | |
| Avg. volume | 732,327 |
| Market cap | 864.752M |
| Beta (5Y monthly) | 1.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.38 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.33 |
GuruFocus.comInsider Buying: Immunome Inc's CEO Acquires 100,000 Shares
On May 21, 2024, Clay Siegall, President and Chief Executive Officer of Immunome Inc (NASDAQ:IMNM), purchased 100,000 shares of the company, as reported in a recent SEC Filing.
Business WireImmunome Announces Completion of Purchase of Assets from Atreca
BOTHELL, Wash., May 20, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of antibodies and related assets from Atreca, Inc. Under the terms of the agreement, Immunome paid Atreca $5.5 million upfront, and Atreca will be eligible for up to $7.0 million in clinical development milestones. Immunome received the rights to 28 antibodies as well as certain materi
Business WireImmunome Announces Promotion of Max Rosett to Chief Financial Officer
BOTHELL, Wash., May 17, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Mr. Rosett most recently held the role of Executive Vice President, Operations, in addition to serving as Immunome’s Interim Chief Financial Officer since January 2024.
